KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Merck (MRK) Asset Utilization Ratio (2009 - 2026)

Merck (MRK) reported Asset Utilization Ratio of 0.5 for Q1 2026, down 10.02% year-over-year from 0.55 in Q1 2025, and up 1.49% on a QoQ basis from 0.49 in Q4 2025.

Merck (MRK) has 18 years of Asset Utilization Ratio data on file, last reported at 0.5 in Q1 2026.

  • Quarterly Asset Utilization Ratio fell 10.02% year-over-year to 0.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.5 (down 10.02% YoY) and the FY2025 annual result came in at 0.51, down 10.73% from the prior year.
  • Asset Utilization Ratio improved to 0.5 in Q1 2026 per MRK's latest filing, from 0.49 in the prior quarter.
  • Across five years, Asset Utilization Ratio topped out at 0.58 in Q1 2024 and bottomed at 0.49 in Q4 2025.
  • The 5-year median for Asset Utilization Ratio is 0.55 (2022), against an average of 0.54.
  • The widest annual swing landed in 2022, when Asset Utilization Ratio increased 12.12%; it then slipped 10.77% in 2025.
  • Tracing MRK's Asset Utilization Ratio over 5 years: stood at 0.55 in 2022, then climbed by 2.75% to 0.56 in 2023, then dropped by 2.92% to 0.55 in 2024, then fell by 10.77% to 0.49 in 2025, then climbed by 1.49% to 0.5 in 2026.
  • Per Business Quant, the three latest MRK Asset Utilization Ratio figures stand at 0.5 (Q1 2026), 0.49 (Q4 2025), and 0.52 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Asset Util. (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 0.63
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 0.48
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 0.46
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 0.50
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 0.41
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 0.52
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 0.12
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 0.55
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.50
Dec 31, 2025 0.49
Sep 30, 2025 0.52
Jun 30, 2025 0.55
Mar 31, 2025 0.55
Dec 31, 2024 0.55
Sep 30, 2024 0.55
Jun 30, 2024 0.57
Mar 31, 2024 0.58
Dec 31, 2023 0.56
Sep 30, 2023 0.56
Jun 30, 2023 0.55
Mar 31, 2023 0.53
Dec 31, 2022 0.55
Sep 30, 2022 0.55
Jun 30, 2022 0.53
Mar 31, 2022 0.51
Dec 31, 2021 0.49
Sep 30, 2021 0.50
Jun 30, 2021 0.48
Mar 31, 2021 0.46
Dec 31, 2020 0.48
Sep 30, 2020 0.40
Jun 30, 2020 0.43
Mar 31, 2020 0.48
Dec 31, 2019 0.47
Sep 30, 2019 0.55
Jun 30, 2019 0.53
Mar 31, 2019 0.52
Dec 31, 2018 0.50
Sep 30, 2018 0.49
Jun 30, 2018 0.48
Mar 31, 2018 0.47
Dec 31, 2017 0.45
Sep 30, 2017 0.43
Jun 30, 2017 0.42
Mar 31, 2017 0.42
Dec 31, 2016 0.41
Sep 30, 2016 0.41
Jun 30, 2016 0.40
Mar 31, 2016 0.39
Dec 31, 2015 0.39
Sep 30, 2015 0.39
Jun 30, 2015 0.38
Mar 31, 2015 0.40
Dec 31, 2014 0.42
Sep 30, 2014 0.43
Jun 30, 2014 0.42
Mar 31, 2014 0.41
Dec 31, 2013 0.42
Sep 30, 2013 0.42
Jun 30, 2012 0.46
Mar 31, 2012 0.46
Dec 31, 2011 0.45
Sep 30, 2011 0.45
Jun 30, 2011 0.44
Mar 31, 2011 0.44
Dec 31, 2010 0.43
Sep 30, 2010 0.41
Jun 30, 2010 0.36
Mar 31, 2010 0.30
Dec 31, 2009 0.38
Sep 30, 2009 0.90